SPOTLIGHT: Late-stage cancer patients are over-tested

Doing screening tests on patients whose life expectancy is extremely limited because of cancer is not cost-effective, according to a new study published in the Journal of the American Medical Association. The study examined the issue of overtesting in late-stage cancer and raises new questions about overdiagnosis and overtreatment in the healthcare system. Too many tests can raise anxiety in patients and lead to unneeded follow-up tests and treatments that can have serious complications, the study found. Article

Suggested Articles

The Affordable Care Act's value-based care programs could go down with the rest of the law, meaning private payers would have to step up.

Blue Cross NC is teaming up with prominent providers and companies in the state to manufacture N95 respirators for healthcare workers.

Health law and health policy experts say Trump has put nothing to rest with his executive order on preexisting conditions. Here’s why.